Carmat – executive interview with Stéphane Piat

Published on 12 January 2021

Carmat is French biotech company that has created the first auto-regulating, bioprosthetic artificial heart able to mimic the natural physiology of the human heart. The company’s mission is to provide cardiologists with innovative technologies that save lives and improve the quality of life for patients with advanced heart failure

In this Edison executive interview, Vivienne Parry, science journalist, author and head of engagement at Genomics England meets with Carmat CEO, Stéphane Piat, to discuss the company’s transformative year, recent CE mark verification and upcoming milestone achievements anticipated for the EFICAS and US feasibility studies in 2021.

Share this with friends and colleagues